As of Aug 27
| -0.27 / -0.84%|
The 6 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 43.50, with a high estimate of 65.00 and a low estimate of 32.00. The median estimate represents a +37.27% increase from the last price of 31.69.
The current consensus among 7 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.